Current Headlines

31. FDA Approves First Cancer Drug Based On Broad Institute Science 11/20/2025

    The US Food and Drug Administration has approved the first cancer drug based on discoveries from Broad Institute scientists. The drug, sevabertinib, was developed by Bayer Healthcare Pharmaceuticals in close collaboration with the Broad, and is the first FDA-approved medicine from the long-standing Broad-Bayer oncology research alliance.

32. SCYNEXIS Completes Transfer Of BREXAFEMME® New Drug Application To GSK 11/19/2025

    SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the transfer of the BREXAFEMME (ibrexafungerp) New Drug Application (NDA) to GSK.

33. Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein And Antibody Solutions 11/19/2025

    At PEGS Europe 2025, one of the industry's premier gatherings for innovation in protein and antibody engineering, Tsingke Biotech highlighted its latest accelerated protein and antibody services.

34. Nuvalent Announces FDA Acceptance Of New Drug Application For Zidesamtinib For The Treatment Of TKI Pre-Treated Patients With Advanced ROS1-Positive NSCLC 11/19/2025

    Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for zidesamtinib, an investigational ROS1-selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least 1 prior ROS1 tyrosine kinase inhibitor (TKI). The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 18, 2026.

35. Nona Biosciences And Pfizer Announce Strategic Research Collaboration To Accelerate Antibody Discovery 11/19/2025

    Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I^® (Idea to IND), today announced a non-exclusive license agreement with Pfizer designed to accelerate preclinical antibody discovery across a range of potential disease indications.

36. Emulate Launches Brain-Chip R1 To Advance Neurological Drug Development, In Partnership With FUJIFILM Cellular Dynamics 11/18/2025

    Emulate, Inc., the leading provider of next-generation Organ-on-a-Chip technology, in partnership with FUJIFILM Cellular Dynamics, Inc., a pioneering global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today announced the launch of the Emulate Brain-Chip R1.

37. DiaGen AI Inc. And Metanova Labs Announce Joint Venture LOI To Develop Hit Picking Tool For Automating Drug Discovery 11/18/2025

    DiaGen AI Inc. (“DiaGen”, or the Company) founded in 2021, established to advance a diverse pipeline of AI drug discovery tools to scale its asset development and provide solutions through its Ai aS A Partner offering to impact traditional drug discovery, is pleased to announce a milestone driven joint venture LOI (the "JV") with Metanova Labs ("Metanova"), pioneers of crypto-native drug discovery with the world’s first decentralized virtual drug screening platform, NOVA, built on the Bittensor network.

38. BioDuro Launches Dedicated Peptide Business Unit, Accelerating Integrated Drug Discovery Solutions 11/18/2025

    BioDuro, a trusted global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of a new Business Unit (BU) dedicated to advancing peptide drug discovery and development for its global biopharma partners, underscoring the company's commitment to strengthening its peptide technology platform to meet the rapidly growing global demand for peptide-based therapeutics, including GLP-1 treatments.

39. GSK And Fleming Initiative Scientists Unite To Target AMR With Advanced AI 11/18/2025

    GSK and the Fleming Initiative today announced six major new research programmes, called ‘Grand Challenges’ which harness some of the best scientific expertise and the latest technologies, including advanced AI, to find new ways to slow the progress of antimicrobial resistance (AMR).

40. Onco-Innovations Advances AI And Quantum Drug Discovery With Kuano Collaboration To Accelerate PNKP Inhibitor Technology Development 11/18/2025

    Onco-Innovations Limited ("Onco" or the "Company”) is pleased to announce that it is initiating a pilot project with Kuano Ltd. (Kuano) to accelerate development of Onco’s PNKP Inhibitor Technology (also known as A83B4C63).